Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population

BACKGROUND. Nivolumab has shown a survival benefit compared with docetaxel as second‐line treatment for patients with previously treated advanced squamous non‐small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients and physicians in routine clinical practice are o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Crinò, Lucio, Bidoli, Paolo, Delmonte, Angelo, Grossi, Francesco, De Marinis, Filippo, Ardizzoni, Andrea, Vitiello, Fabiana, Lo Russo, Giuseppe, Parra, Hector Soto, Cortesi, Enrico, Cappuzzo, Federico, Calabrò, Luana, Tiseo, Marcello, Turci, Daniele, Gamucci, Teresa, Antonelli, Paola, Morabito, Alessandro, Chella, Antonio, Giannarelli, Diana, Galetta, Domenico
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2019
Предметы:
Lung Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853127/
https://ncbi.nlm.nih.gov/pubmed/30996007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0737
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы